

Figure S1. Immune response to atezolizumab plus bevacizumab in treatment-naïve patients (a) Heatmap of the median frequencies of 32 $CD4^+$ and $CD8^+$ T-cell phenotypes in PR+SD and PD at baseline and week 3 in 11 patients receiving first-line atezolizumab plus bevacizumab. (b) Box plots of the frequencies of T-cell phenotypes in PR+SD (n = 7) and PD (n = 4). **P < 0.05, *P < 0.1 according to Wilcoxon matched-pair signed-rank test. (c) Box plots of differences in the baseline frequencies of the indicated T-cell phenotypes in PR+SD and PD. **P < 0.05, *P < 0.1 according to Mann–Whitney U-test.